Sumit Kumar, MD
Nephrology · Dallas, TXNPI 1598743098
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,340 of the $166,486 with a category attached, or 77.7%. 36 manufacturers reported payments, led by Aurinia Pharma U.S., Inc. at 27.2% of the total. Reporting peaked in 2024 at $60,851 and has fallen 67.3% since, to $19,915 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $357.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$45K
- Boehringer Ingelheim$33K
- Amgen$33K
- Lilly USA, LLC$24K
- Travere Therapeutics, Inc.$17K
- Novartis$8K
- plus $7K from 30 others
Across 137 payments — averaging $2882.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$178K
- Genentech, Inc.$61K
- Travere Therapeutics, Inc.$36K
- Hoffmann-la Roche Limited$35K
- Vertex$25K
- AstraZeneca$16K
- plus $44K from 5 others
What the payments were for
- Consulting fees$6,5744%
- Speaking & faculty fees$129,34078%
- Travel & lodging$19,22212%
- Food & beverage$11,0727%
- Education$2790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 60 | $45,206 |
| Boehringer Ingelheim | 39 | $33,371 |
| Amgen(2 entities) | 109 | $32,796 |
| Lilly USA, LLC | 26 | $23,515 |
| Travere Therapeutics, Inc. | 48 | $16,917 |
| Novartis | 19 | $7,651 |
| AstraZeneca(2 entities) | 18 | $1,285 |
| Intuitive Surgical | 5 | $1,190 |
| Johnson & Johnson(2 entities) | 5 | $435 |
| Cormedix Inc. | 4 | $365 |
| Calliditas Therapeutics US Inc. | 7 | $365 |
| Mallinckrodt Hospital Products Inc. | 15 | $360 |
| Boston Scientific | 1 | $333 |
| Otsuka America Pharmaceutical, Inc. | 15 | $326 |
| Fresenius USA Marketing, Inc. | 17 | $317 |
| Ardelyx, Inc. | 8 | $241 |
| Bayer | 16 | $211 |
| OPKO Pharmaceuticals, LLC | 10 | $175 |
| Teleflex LLC | 1 | $145 |
| Vifor Pharma, Inc. | 7 | $140 |
| GSK | 3 | $124 |
| Akebia Therapeutics Inc | 7 | $121 |
| Mallinckrodt Enterprises LLC | 2 | $115 |
| La Jolla Pharmaceutical Company | 1 | $108 |
| Outset Medical Inc | 1 | $101 |
| Novo Nordisk | 5 | $91 |
| Alnylam Pharmaceuticals Inc. | 3 | $78 |
| Philips North America LLC | 1 | $71 |
| Renalytix AI, Inc. | 3 | $69 |
| Sanofi | 3 | $65 |
| Vertex | 1 | $56 |
| Genentech, Inc. | 1 | $52 |
| Scpharmaceuticals Inc. | 2 | $42 |
| Shire North American Group Inc | 1 | $21 |
| Medtronic | 1 | $18 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$56,264
- LUPKYNIS$39,888
- KRYSTEXXA$31,498
- Fabhalta$7,293
- Da Vinci Surgical System$1,165
- FARXIGA$787
- INVOKANA$375
- 2CM PERIPHERAL CUTTING BALLOON$333
- DefenCath$323
- GUIDELINER$145
- XPHOZAH 30 MG$110
- GIAPREZA$108
- TARPEYO$101
How this compares
$166,486 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 226 | $215,366 |
| JardianceEmpagliflozin | 192 | $171,641 |
| KerendiaFinerenone | 89 | $108,442 |
| RayaldeeCalcifediol | 53 | $65,378 |
| MounjaroTirzepatide | 28 | $29,136 |
| OzempicSemaglutide | 20 | $19,036 |
| Sevelamer Carbonate | 63 | $15,317 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $13,625 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $13,315 |
| Clonidine | 20 | $3,973 |
| Mycophenolate Mofetil | 22 | $2,623 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,602 |
| Allopurinol | 267 | $1,913 |
| Nifedipine ErNifedipine | 69 | $1,652 |
| Torsemide | 86 | $1,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,285 | $228,681247 claims |
| Boehringer IngelheimJardiance | $33,371 | $171,641192 claims |
| BayerKerendia | $211 | $108,44289 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $175 | $65,37853 claims |
| Lilly USA, LLCMounjaro | $23,515 | $29,13628 claims |
| Novo NordiskOzempic | $91 | $19,03620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Dallas
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Irfan AghaDallas$415K
- Russell SilversteinDallas$204K
- Christopher HebertDallas$102K
- Robert TotoDallas$87K
- Michael WiederkehrDallas$82K
- Samir ParikhDallas$72K
- Joseph LockridgeDallas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.